Estrogen receptor-negative invasive breast cancer: Imaging features of tumors with and without human epidermal growth factor receptor type 2 overexpression

Radiology

Volumn 246, Issue 2, 2008, Pages 367-375

  Wang, Yingbing ^a   Ikeda, Debra M ^a   Narasimhan, Balasubramanian ^a   Longacre, Teri A ^a   Bleicher, Richard J ^b   Pal, Sunita ^a   Jackman, Roger J ^a   Jeffrey, Stefanie S ^a  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b FOX CHASE CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; PROGESTERONE RECEPTOR; ERBB2 PROTEIN, HUMAN; TUMOR MARKER; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; BREAST CALCIFICATION; BREAST CANCER; CANCER INVASION; CANCER STAGING; ECHOMAMMOGRAPHY; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; GENE OVEREXPRESSION; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; INFORMED CONSENT; MAJOR CLINICAL STUDY; MAMMOGRAPHY; MOLECULAR GENETICS; ONCOGENE NEU; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROTEIN EXPRESSION; BREAST TUMOR; CALCINOSIS; CLASSIFICATION; COMPARATIVE STUDY; MALE; METABOLISM; METHODOLOGY; MIDDLE AGED; REPRODUCIBILITY; SENSITIVITY AND SPECIFICITY;

ADULT; AGED; AGED, 80 AND OVER; BREAST NEOPLASMS; CALCINOSIS; FEMALE; HUMANS; MALE; MAMMOGRAPHY; MIDDLE AGED; RECEPTOR, ERBB-2; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY; TUMOR MARKERS, BIOLOGICAL;

EID: 39549101230     PISSN: 00338419     EISSN: 15271315     Source Type: Journal    
DOI: 10.1148/radiol.2462070169     Document Type: Article

References (46)

1. Putti TC, El-Rehim DM, Rakha EA, et al. Estrogen receptor-negative breast carcinomas: a review of morphology and immunophenotypical analysis. Mod Pathol 2005;18:26-35.
2. Parl FF, Schmidt BP, Dupont WD, Wagner RK. Prognostic significance of estrogen receptor status in breast cancer in relation to tumor stage, axillary node metastasis, and histopathologic grading. Cancer 1984;54:2237-2242.
3. Carey LA, Dees EC, Sawyer L, et al. The triple negative paradox: primary tumor chemosensitivity of breast cancer subtypes. Clin Cancer Res 2007;13:2329-2334.
4. Pichon MF, Broet P, Magdelenat H, et al. Prognostic value of steroid receptors after long-term follow-up of 2257 operable breast cancers. Br J Cancer 1996;73:1545-1551.
5. Howell A, Cuzick J, Baum M, et al. Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years' adjuvant treatment for breast cancer. Lancet 2005;365:60-62.
6. Paone JF, Abeloff MD, Ettinger DS, Arnold EA, Baker RR. The correlation of estrogen and progesterone receptor levels with response to chemotherapy for advanced carcinoma of the breast. Surg Gynecol Obstet 1981;152:70-74.
7. Slamon DJ, Godolphin W, Jones LA, et al. Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science 1989;244:707-712.
8. Pegram M, Slamon D. Biological rationale for HER2/neu (c-erbB2) as a target for monoclonal antibody therapy. Semin Oncol 2000;27:13-19.
9. Konecny G, Pauletti G, Pegram M, et al. Quantitative association between HER-2/neu and steroid hormone receptors in hormone receptor-positive primary breast cancer. J Natl Cancer Inst 2003;95:142-153.
10. Stefano R, Agostara B, Calabro M, et al. Expression levels and clinical-pathological correlations of HER2/neu in primary and metastatic human breast cancer. Ann N Y Acad Sci 2004;1028:463-472.
11. Slamon DJ, Leyland-Jones B, Shak S, et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 2001;344:783-792.
12. Vogel CL, Cobleigh MA, Tripathy D, et al. Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer. J Clin Oncol 2002;20:719-726.
13. Romond EH, Perez EA, Bryant J, et al. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med 2005;353:1673-1684.
14. Joensuu H, Kellokumpu-Lehtinen PL, Bono P, et al. Adjuvant docetaxel or vinorelbine with or without trastuzumab for breast cancer. N Engl J Med 2006;354:809-820.
15. Smith I, Procter M, Gelber RD, et al. 2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: a randomised controlled trial. Lancet 2007;369:29-36.
16. Siziopikou KP, Ariga R, Proussaloglou KE, Gattuso P, Cobleigh M. The challenging estrogen receptor-negative/progesterone receptor-negative/HER-2- negative patient: a promising candidate for epidermal growth factor receptor-targeted therapy? Breast J 2006;12:360-362.
17. Carey LA, Perou CM, Livasy CA, et al. Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study. JAMA 2006;295:2492-2502.
18. Kim MJ, Ro JY, Ahn SH, Kim HH, Kim SB, Gong G. Clinicopathologic significance of the basal-like subtype of breast cancer: a comparison with hormone receptor and Her2/neu-overexpressing phenotypes. Hum Pathol 2006;37:1217-1226.
19. Jeffrey SS, Lonning PE, Hillner BE. Genomics-based prognosis and therapeutic prediction in breast cancer. J Natl Compr Canc Netw 2005;3:291-300.
20. Elston CW, Ellis IO. Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long-term follow-up. Histopathology 1991;19:403-410.
21. Choi DH, Shin DB, Lee MH, et al. A comparison of five immunohistochemical biomarkers and HER-2/neu gene amplification by fluorescence in situ hybridization in white and Korean patients with early-onset breast carcinoma. Cancer 2003;98:1587-1595.
22. Dybdal N, Leiberman G, Anderson S, et al. Determination of HER2 gene amplification by fluorescence in situ hybridization and concordance with the clinical trials immunohistochemical assay in women with metastatic breast cancer evaluated for treatment with trastuzumab. Breast Cancer Res Treat 2005;93:3-11.
23. American College of Radiology. Breast Imaging and Reporting Data System (BIRADS). Reston, Va: American College of Radiology, 2003.
24. R Development Core Team. R: a language and environment for statistical computing. Vienna, Austria: R Foundation for Statistical Computing, 2006.
25. Yu D, Hung MC. Overexpression of ErbB2 in cancer and ErbB2-targeting strategies. Oncogene 2000;19:6115-6121.
26. Hong AS, Rosen EL, Soo MS, Baker JA. BIRADS for sonography: positive and negative predictive values of sonographic features. AJR Am J Roentgenol 2005;184:1260-1265.
27. Liberman L, Abramson AF, Squires FB, Glassman JR, Morris EA, Dershaw DD. The breast imaging reporting and data system: positive predictive value of mammographic features and final assessment categories. AJR Am J Roentgenol 1998;171:35-40.
28. Kaas R, Kroger R, Peterse JL, Hart AA, Muller SH. The correlation of mammographic-and histologic patterns of breast cancers in BRCA1 gene mutation carriers, compared to age-matched sporadic controls. Eur Radiol 2006;16:2842-2848.
29. Rakha EA, El-Sayed ME, Green AR, Lee AH, Robertson JF, Ellis IO. Prognostic markers in triple-negative breast cancer. Cancer 2007;109:25-32.
30. Hamilton LJ, Evans AJ, Wilson AR, et al. Breast imaging findings in women with BRCA1- and BRCA2-associated breast carcinoma. Clin Radiol 2004;59:895-902.
31. Ildefonso C, Vazquez J, Guinea O, et al. The mammographic appearance of breast carcinomas of invasive ductal type: relationship with clinicopathological parameters, biological features and prognosis. Eur J Obstet Gynecol Reprod Biol doi:10.1016/j.ejogrb.2006.10.025. Published online November 20, 2006. Accessed April 25, 2007.
32. Alexander MC, Yankaskas BC, Biesemier KW. Association of stellate mammographic pattern with survival in small invasive breast tumors. AJR Am J Roentgenol 2006;187:29-37.
33. Nicolau M, Tibshirani R, Borresen-Dale AL, Jeffrey SS. Disease-specific genomic analysis: identifying the signature of pathologic biology. Bioinformatics 2007;23:957-965.
34. Seo BK, Pisano ED, Kuzimak CM, et al. Correlation of HER-2/neu overexpression with mammography and age distribution in primary breast carcinomas. Acad Radiol 2006;13:1211-1218.
35. Tabar L, Tony Chen HH, Amy Yen MF, et al. Mammographic tumor features can predict long-term outcomes reliably in women with 1-14-mm invasive breast carcinoma. Cancer 2004;101:1745-1759.
36. Thurfjell E, Thurfjell MG, Lindgren A. Mammographic finding as predictor of survival in 1-9 mm invasive breast cancers: worse prognosis for cases presenting as calcifications alone. Breast Cancer Res Treat 2001;67:177-180.
37. Munzone E, Curigliano G, Rocca A, et al. Reverting estrogen-receptor- negative phenotype in HER-2-overexpressing advanced breast cancer patients exposed to trastuzumab plus chemotherapy. Breast Cancer Res 2006;8:R4. [Published correction appears in Breast Cancer Res 2006;8:407.]
38. Fan C, Oh DS, Wessels L, et al. Concordance among gene-expression-based predictors for breast cancer. N Engl J Med 2006;355:560-569.
39. Perou CM, Sorlie T, Eisen MB, et al. Molecular portraits of human breast tumours. Nature 2000;406:747-752.
40. Sorlie T, Perou CM, Tibshirani R, et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci U S A 2001;98:10869-10874.
41. Sorlie T, Tibshirani R, Parker J, et al. Repeated observation of breast tumor subtypes in independent gene expression data sets. Proc Natl Acad Sci U S A 2003;100:8418-8423.
42. Hu Z, Fan C, Oh DS, et al. The molecular portraits of breast tumors are conserved across microarray platforms. BMC Genomics 2006;7:96.
43. Sotiriou C, Neo SY, McShane LM, et al. Breast cancer classification and prognosis based on gene expression profiles from a population-based study. Proc Natl Acad Sci U S A 2003;100:10393-10398.
44. Yu K, Lee CH, Tan PH, Tan P. Conservation of breast cancer molecular subtypes and transcriptional patterns of tumor progression across distinct ethnic populations. Clin Cancer Res 2004;10:5508-5517.
45. Zhao H, Langerod A, Ji Y, et al. Different gene expression patterns in invasive lobular and ductal carcinomas of the breast. Mol Biol Cell 2004;15:2523-2536.
46. Livasy CA, Karaca G, Nanda R, et al. Phenotypic evaluation of the basal-like subtype of invasive breast carcinoma. Mod Pathol 2006;19:264-271.